India, Aug. 20 -- Herantis Pharma Oyj (HRTIS.HE), a clinical-stage biotechnology company, on Wednesday released interim financial results for the first half of 2026, noting a slightly higher loss due to increased expenses.
The Finnish company develops therapies to limit the progression of Parkinson's disease. It's lead drug candidate, HER-096, demonstrated a neuroprotective mechanism of the cerebral dopamine neurotrophic factor (CDNF), and is administered subcutaneously. H1 Financial Highlights:
The company's net loss narrowed to EUR 3.32 million in the first half of 2026, relatively lower than the EUR 3.20 million reported in the same period of 2025.
The increased loss can be attributed to higher expenses associated with advancing the c...